References
- Meinardi MT, Gietema JA, van Veldhuisen DJ, van der Graaf WT, Vries EG, Sleijfer DT. Long-term chemotherapyrelated cardiovascular morbidity. Cancer Treat Rev 2000;26: 429-47 https://doi.org/10.1053/ctrv.2000.0175
- von Hoff DD, Layard MW, Basa P, Davis HL Jr, von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-in-duced congestive heart failure. Ann Intern Med 1979;91: 710-7 https://doi.org/10.7326/0003-4819-91-5-710
- Massin MM, Dresse MF, Schimitz V, Hoyoux C, Chantraine JM, Lepage P. Acute arrhythmogenicity of first-dose chemotherapeutic agents in children. Med Pediatr Oncol 2002; 39:93-8 https://doi.org/10.1002/mpo.10123
- Simbre VC, Duffy SA, Dadlani GH, Miller TL, Lipshultz SE. Cardiotoxicity of cancer chemotherapy: implications for children. Paediatr Drugs 2005;7:187-202 https://doi.org/10.2165/00148581-200507030-00005
- Shan K, Lincoff M, Young JB. Anthracycline induced cardiotoxicity. Ann Intern Med 1996;125:47-58 https://doi.org/10.7326/0003-4819-125-1-199607010-00008
- Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 1995;24:352-61 https://doi.org/10.1002/mpo.2950240103
- Ganz WI, Sridhar KS, Ganz SS, Gonzalez R, Chakko S, Serafini A. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 1996;53:461-70 https://doi.org/10.1159/000227621
- Villani F, Meazza R, Materazzo C. Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: comparison with echocardiography. Anticancer Res 2006;26:797-801
- Wilkins MR, Redondo J, Brown LA. The natriuretic-peptide family. Lancet 1997;349:1307-10 https://doi.org/10.1016/S0140-6736(96)07424-7
- Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 2004;6:261-8 https://doi.org/10.1016/j.ejheart.2004.01.004
- Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Circulation 1996; 93:1963-9 https://doi.org/10.1161/01.CIR.93.11.1963
- McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003;4:72-80
- Kunii Y, Kamada M, Ohtsuki S, Araki T, Kataoka K, Kageyama M, et al. Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med Okayama 2003;57:191-7
- Bernstein D. Heart failure. In: Behrman RE, Kliegman RM, Jenson HB, editors. Nelson textbook of pediatrics. 17th ed. Philadelphia: WB Saunders Co, 2004:1583-4
- Triage BNP Test Product Insert. San Diego CA: Biosite Diagnostics Inc. 2000
- Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart 2003;89:875-8 https://doi.org/10.1136/heart.89.8.875
- Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998;25 (Suppl 10):72-85
- Doroshow JH. Doxorubicin-induced cardiototoxicity. N Engl J Med 1991;324:843-5 https://doi.org/10.1056/NEJM199103213241210
- Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 1980;65:128-35 https://doi.org/10.1172/JCI109642
- Larsen RL, Jakacki RI, Vetter VL, Meadows AT, Silber JH, Barber G. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 1992;70:73-7 https://doi.org/10.1016/0002-9149(92)91393-I
- Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Safety 2000;22:263-302 https://doi.org/10.2165/00002018-200022040-00002
- Alderton PM, Gross J, Green MD. Comparative study of doxorubicin, mitoxantrone and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res 1992;52:194-201
- Cirillo R, Sacco G, Venturella S, Brightwell J, Giachetti A, Manzini S. Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat. J Cardiovasc Pharmacol 2000;35:100-8 https://doi.org/10.1097/00005344-200001000-00013
- Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children Cancer Study Group. Pediatrics 1992;89:942-9
- Sparano JA, Brown DL, Wolff AC. Predicting cancer therapy- induced cardiotoxicity: the role of troponins and other markers. Drug Safety 2002;25:301-11 https://doi.org/10.2165/00002018-200225050-00001
- Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, et al. Predictive value of cardiac troponin-T in pediatric patients at risk for myocardial injury. Circulation 1997;96:2641-8 https://doi.org/10.1161/01.CIR.96.8.2641
- Davidson NC, Naas AA, Hanson JK, Kennedy NS, Coutie WJ, Struthers AD. Comparison of atrial natriuretic peptide, B-type natriuretic peptide and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 1996;77:828-31 https://doi.org/10.1016/S0002-9149(97)89176-X
- Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1347-51
- Suzuki T, Hayashi D, Yamazaki T, Mizuno T, Kanda Y, Komuro I, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998;136:362-3 https://doi.org/10.1053/hj.1998.v136.89908
- Daugaard G, Lassen U, Bie P, Pedersen EB, Jensen KT, Abildgaard U, et al. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 2005;7:87-93 https://doi.org/10.1016/j.ejheart.2004.03.009
- Elbl L, Vasova I, Navratil M, Vorlicek J, Malaskova L, Spinar J. Comparison of plasmatic levels of B-natriuretic peptide with echocardiographic indicators of left ventricle function after doxorubicin therapy. Vnitr Lek 2006;52:563-70
- Pinarli FG, Oguz A, Tunaoglu FS, Karadeniz C, Gokcora N, Elbeg S. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr Blood Cancer 2005;44:370-7 https://doi.org/10.1002/pbc.20281
- Aggarwal S, Pettersen MD, Bhambhani K, Gurczynski J, Thomas R, L'ecuyer T. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatric Blood Cancer. Early View. Published Online: 2006 Dec
- Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001;37:4-9 https://doi.org/10.1002/mpo.1155